Compare Neurocrine Biosciences Inc (NBIX) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Sirius XM Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SIRI | |
|---|---|---|
Market Cap | $15.77B | $9.71B |
Sector | Health | Media |
52-Week High | $185.50 | $32.59 |
52-Week Low | $123.10 | $19.92 |
Enterprise Value | $15.78B | $18.99B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Sirius XM Holdings Inc. (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $34.86. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Financials show a net income margin of 10.23% for 2025, with revenue at $8.56B, while the balance sheet indicates a debt-to-asset ratio improvement to 35.63% in 2025. Recent news highlights a YouTube partnership expected to boost EBITDA by 2029.
The outlook for SIRI is positive, supported by analyst upgrades and institutional buying, but risks include competitive pressures in audio streaming and reliance on advertising growth. The stock's valuation metrics, such as a P/E of 11.57 and P/B of 0.82, suggest potential upside if earnings improve, though volatility from market sentiment remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
